Steven Schultz from Momentum chose Pfizer as his stock pick of the day.

“Pfizer pharmaceuticals is a US-listed offshore company. I think it is a great environment to take a very defensive growth counter such as Pfizer. It is in the headlines at the moment for its acquisition of Array Biopharma for $10.64bn in cash. It is effectively an oncology portfolio, which bolts on quite nicely to Pfizer. Not a cheap counter by any measure at the moment but it does boast a pretty impressive dividend yield of 3.3% in US dollar terms.”..

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.